In Vitro Characterization of GS-8374, a Novel Phosphonate-Containing Inhibitor of HIV-1 Protease with a Favorable Resistance Profile

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Antimicrobial Agents and Chemotherapy

• Publication date

  2011-01-18

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1128/AAC.01183-10PMID 21245449PMCID PMC3067135
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Metabolic Complications Associated with HIV Protease Inhibitor Therapy

  2012cited by this paper
• GS-8374, a Novel HIV Protease Inhibitor, Does Not Alter Glucose Homeostasis in Cultured Adipocytes or in a Healthy-Rodent Model System

  2011cited by this paper
• Fifteen years of HIV Protease Inhibitors: raising the barrier to resistance.

  2010cited by this paper
• The evolution of HIV treatment guidelines: current state-of-the-art of ART.

  2010influential reference
• Raltegravir, Etravirine, and Ritonavir-Boosted Darunavir: A Safe and Successful Rescue Regimen for Multidrug-Resistant HIV-1 Infection

  2009cited by this paper
• Pharmacokinetic enhancers for HIV drugs.

  2009cited by this paper
• Human Immunodeficiency Virus in an Aging Population, a Complication of Success

  2009influential reference
• Update of the drug resistance mutations in HIV-1: December 2009.

  2009cited by this paper
• Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis

  2009cited by this paper
• High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial.

  2009cited by this paper
• Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance.

  2008cited by this paper
• In Vitro Antiviral Activity of the Novel, Tyrosyl-Based Human Immunodeficiency Virus (HIV) Type 1 Protease Inhibitor Brecanavir (GW640385) in Combination with Other Antiretrovirals and against a Panel of Protease Inhibitor-Resistant HIV

  2007cited by this paper
• Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein.

  2007cited by this paper
• A Novel Substrate-Based HIV-1 Protease Inhibitor Drug Resistance Mechanism

  2007cited by this paper
• Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials.

  2007cited by this paper
• Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial.

  2007cited by this paper
• Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: the discovery of GW0385.

  2006cited by this paper
• Suppression of HIV-1 protease inhibitor resistance by phosphonate-mediated solvent anchoring.

  2006cited by this paper
• Clinical pharmacodynamics of HIV-1 protease inhibitors: use of inhibitory quotients to optimise pharmacotherapy.

  2006cited by this paper
• Endoplasmic Reticulum Stress Links Dyslipidemia to Inhibition of Proteasome Activity and Glucose Transport by HIV Protease Inhibitors

  2005cited by this paper
• Discovery of next generation inhibitors of HIV protease.

  2005cited by this paper
• Novel P1 chain-extended HIV protease inhibitors possessing potent anti-HIV activity and remarkable inverse antiviral resistance profiles.

  2005cited by this paper
• TMC114, a Novel Human Immunodeficiency Virus Type 1 Protease Inhibitor Active against Protease Inhibitor-Resistant Viruses, Including a Broad Range of Clinical Isolates

  2005cited by this paper
• Atazanavir inhibits P-glycoprotein and multidrug resistance-associated protein efflux activity.

  2005cited by this paper
• Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor.

  2005cited by this paper
• Acquisition of multi-PI (protease inhibitor) resistance in HIV-1 in vivo and in vitro.

  2004cited by this paper
• The prevalence of antiretroviral drug resistance in the United States

  2004cited by this paper
• Tolerability and Safety of HIV Protease Inhibitors in Adults

  2004cited by this paper
• Worldwide transmission of drug-resistant HIV.

  2003cited by this paper
• Toxicity of antiretroviral therapy and implications for drug development

  2003cited by this paper
• Resistance of HIV-1 to multiple antiretroviral drugs in France: a 6-year survey (1997–2002) based on an analysis of over 7000 genotypes

  2003cited by this paper
• Antiviral activity of UIC-PI, a novel inhibitor of the human immunodeficiency virus type 1 protease.

  2002cited by this paper
• A Potent Human Immunodeficiency Virus Type 1 Protease Inhibitor, UIC-94003 (TMC-126), and Selection of a Novel (A28S) Mutation in the Protease Active Site

  2002cited by this paper
• Antiretroviral-drug resistance among patients recently infected with HIV.

  2002cited by this paper
• Highly Active Antiretroviral Therapy Decreases Mortality and Morbidity in Patients with Advanced HIV Disease

  2001cited by this paper
• Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, February 5, 2001

  2001cited by this paper
• Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults

  2001cited by this paper
• Determination of interaction kinetic constants for HIV-1 protease inhibitors using optical biosensor technology.

  2001cited by this paper
• The binding energetics of first- and second-generation HIV-1 protease inhibitors: implications for drug design.

  2001cited by this paper
• Human immunodeficiency virus type-1 protease inhibitors: therapeutic successes and failures, suppression and resistance.

  2000cited by this paper
• Exact analysis of competition ligand binding by displacement isothermal titration calorimetry.

  2000cited by this paper
• BMS-232632, a Highly Potent Human Immunodeficiency Virus Protease Inhibitor That Can Be Used in Combination with Other Available Antiretroviral Agents

  2000cited by this paper
• A Novel Phenotypic Drug Susceptibility Assay for Human Immunodeficiency Virus Type 1

  2000cited by this paper
• Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes.

  1999cited by this paper
• Combination antiretroviral therapy and recent declines in AIDS incidence and mortality.

  1999cited by this paper
• Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, January 28, 2000

  1998cited by this paper
• Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators.

  1998cited by this paper
• Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection.

  1998cited by this paper
• Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.

  1998cited by this paper
• Strategic design and three-dimensional analysis of antiviral drug combinations

  1993cited by this paper
• A three-dimensional model to analyze drug-drug interactions.

  1990cited by this paper

• Advancements in development of novel class of HIV protease inhibitors

  2026cites this paper
• On-Resin Assembly of Macrocyclic Inhibitors of Cryptococcus neoformans May1: A Pathway to Potent Antifungal Agents

  2025cites this paper
• Phenotypic Characterization of Replication‐Impaired Lenacapavir‐Resistant HIV Clinical Isolates

  2025cites this paper
• Development of Anti-HIV Therapeutics: From Conventional Drug Discovery to Cutting-Edge Technology

  2024cites this paper
• Preclinical characterization of a non-peptidomimetic HIV protease inhibitor with improved metabolic stability

  2024cites this paper
• HIV-1 protease inhibitors with a P1 phosphonate modification maintain potency against drug-resistant variants by increased interactions with flap residues.

  2023cites this paper
• Inhibiting HTLV-1 Protease: A Viable Antiviral Target.

  2021cites this paper
• Re-emerging Aspartic Protease Targets: Examining Cryptococcus neoformans Major Aspartyl Peptidase 1 as a Target for Antifungal Drug Discovery

  2021cites this paper
• Drug Design Strategies to Avoid Resistance in Direct-Acting Antivirals and Beyond.

  2021cites this paper
• New heteroaryl carbamates: Synthesis and biological screening in vitro and in mammalian cells of wild-type and mutant HIV-protease inhibitors.

  2019cites this paper
• Protease Inhibitors for the Treatment of HIV/AIDS: Recent Advances and Future Challenges.

  2019cites this paper
• Quantitative structure activity/pharmacokinetics relationship studies of HIV-1 protease inhibitors using three modelling methods.

  2019cites this paper
• Major Qualifying Projects ( All Years ) Major Qualifying Projects April 2017 Synthesis and Evaluation of New HIV-1 Protease Inhibitors

  2019cites this paper
• Viability of primary osteoblasts after treatment with tenofovir alafenamide: Lack of cytotoxicity at clinically relevant drug concentrations

  2017cites this paper
• Highly active group 11 metal complexes with α-hydrazidophosphonate ligands.

  2017cites this paper
• Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS.

  2016cites this paper
• In Vitro Virology Profile of Tenofovir Alafenamide, a Novel Oral Prodrug of Tenofovir with Improved Antiviral Activity Compared to That of Tenofovir Disoproxil Fumarate

  2015cites this paper
• HIV‐1 Protease Inhibitors for the Treatment of HIV Infection and AIDS: Design of Saquinavir, Indinavir, and Darunavir

  2015cites this paper
• Intramolecular indicator displacement assay for anions: supramolecular sensor for glyphosate.

  2014cites this paper
• Structure-based Design of Drugs and Other Bioactive Molecules: Tools and Strategies

  2014cites this paper
• Protease-MediatedMaturation of HIV : Inhibitors of Protease and theMaturation Process

  2014cites this paper
• Prototype Phosphonate-Containing Inhibitor of HIV-1 Protease , Effectively 1 Inhibits Protease Mutants with Amino Acid Insertions 2 3 Running title : HIV-1 Protease Mutants and Phosphonate Inhibitor 4 5

  2013cites this paper
• Antiviral Drug Discovery

  2013cites this paper
• First supramolecular sensors for phosphonate anions

  2013cites this paper
• Recent patents and emerging therapeutics for HIV infections: a focus on protease inhibitors.

  2013cites this paper
• Synthesis and biological evaluation of phosphonate analogues of nevirapine.

  2013cites this paper
• P2′ Benzene Carboxylic Acid Moiety Is Associated with Decrease in Cellular Uptake: Evaluation of Novel Nonpeptidic HIV-1 Protease Inhibitors Containing P2 bis-Tetrahydrofuran Moiety

  2013cites this paper
• GS-8374, a Prototype Phosphonate-Containing Inhibitor of HIV-1 Protease, Effectively Inhibits Protease Mutants with Amino Acid Insertions

  2013cites this paper
• Viral proteases as targets for drug design.

  2012cites this paper
• Cobicistat Boosts the Intestinal Absorption of Transport Substrates, Including HIV Protease Inhibitors and GS-7340, In Vitro

  2012cites this paper
• Verstärkung der Bindung an das Proteinrückgrat – ein fruchtbares Konzept gegen die Arzneimittelresistenz von HIV†

  2012cites this paper
• Oxoquinoline acyclonucleoside phosphonate analogues as a new class of specific inhibitors of human immunodeficiency virus type 1.

  2012cites this paper
• Enhancing Protein Backbone Binding—A Fruitful Concept for Combating Drug‐Resistant HIV†

  2012cites this paper
• Protease-Mediated Maturation of HIV: Inhibitors of Protease and the Maturation Process

  2012cites this paper
• Mutations in Multiple Domains of Gag Drive the Emergence of In Vitro Resistance to the Phosphonate-Containing HIV-1 Protease Inhibitor GS-8374

  2012cites this paper
• Discovery of GS-8374, a potent human immunodeficiency virus type 1 protease inhibitor with a superior resistance profile

  2011cites this paper
• GS-8374, a Novel HIV Protease Inhibitor, Does Not Alter Glucose Homeostasis in Cultured Adipocytes or in a Healthy-Rodent Model System

  2011cites this paper